Prescription drug abuse and methods of diversion the potential role of a pharmacy network

Journal of Substance Use

Volumn 14, Issue 2, 2009, Pages 75-83

  Elaneed, A ^a   Alaghehbandan, R ^b   Gladney, N ^b   Collins, K ^b   MacDonald, D ^b   Fischer, B ^c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Newfoundland and Labrador Centre for Health Information   (Canada)

^c UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Drug diversion; Electronic health records; Pharmacy network; Prescription drug abuse

Indexed keywords

ARTICLE; CANADA; DRUG ABUSE; FORGERY; INTERNET; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 70749124152     PISSN: 14659891     EISSN: 14759942     Source Type: Journal    
DOI: 10.1080/14659890802446087     Document Type: Article

References (46)

1. Barrett, S. P., Darredeau, C., Bordy, L. E., & Pihl, R. O. (2005). Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry, 50, 457-461.
2. Barrett, S. P., Darredeau, C., & Pihl, R. O. (2006). Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacology, 21, 255-263.
3. Batten, H. L., Prottas, J. M., Horgan, C. M., Simon, L. J., Larson, M. J., & Elliott, E. A., et al. (1992). Drug services research survey. Phase II final report. Waltham: Bigel Institute for Health Policy, Brandeis University.
4. Bird, S. (2006). Prescribing schedule 8 drugs. Australian Family Physician, 35, 59-60.
5. Boeuf, O., & Lapeyre-Mestre, M. (2007). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Safety, 30, 265-276.
6. Bollinger, S. L., Bush, C., Chenault, K. I., Curtis, J. L., Dimon, J., & Dolan, P. R., et al. (2005). Under the counter: The diversion and abuse of controlled prescription drugs in the U.S. The National Center on Addiction and Substance Abuse at Columbia University (CASA). Accessed from http://www.casacolumbia.org/absolutenm/ arbiclefiles/380- Under%20the%20Counter%20-%20Diversion.pdf.
7. Brushwood, D. B., & Kimberlin, C. A. (2004). Media coverage of controlled substance diversion through theft or loss. Journal of the American Pharmaceutical Association, 44, 439-444.
8. Canadian Center on Substance Abuse. (2007). Prescription Drug Abuse FAQs. Accessed from http://www.ccsa.ca/ 2006%20CCSA%20Documents/ccsa-011332-2006.pdf.
9. Fischer, B., Brissette, S., Brochu, S., Bruneau, J., El Guebaly, N., & Noel, L., et al. (2004). Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. Canadian Medical Association Journal, 171, 235-239.
10. Fischer, B., Rehm, J., Patra, J., & Cruz, M. F. (2006). Changes in illicit opioid use across Canada. Canadian Medical Association Journal, 175, 1385-1387.
11. Foran, A. (2007). NSPMP's Board Resolution Regarding on-line System. PMP Bulletin. Prescription Monitoring in Nova Scotia. Halifax, NS, Canada. Avaliable on line: http://www.cpsns.ns.ca/2007-july-pmp-bulletin.pdf
12. Foran, A. (2006). PMP Bulletin. Prescription Monitoring in Nova Scotia. Halifax, NS, Canada. Accessed from http://www.cpsns.ns.ca/2006-may-pmp-bulletin. pdf.
13. Goodwin, R. D., & Hasin, D. S. (2002). Sedative use and misuse in the United States. Addiction, 97, 555-562.
14. Grzybowski, S. (2004). The black market in prescription drugs. Lancet, 364, 28-29.
15. Health Canada. (2006). Abuse and diversion of controlled substances: A guide for health professionals. Accessed from http:// www.pdbns.ca/Resources/ Docs/Health%20Canada%20-%20A%20Guide%20for%20Health%20Professionals% 20-%20English.pdf.
16. Huang, B., Dawson, D. A., Stinson, F. S., Hasin, D. S., Ruan, W. J., & Saha, T. D., et al. (2006). Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 67, 1062-1073. (Pubitemid 44230877)
17. Hughes, G. F., McElnay, J. C., Hughes, C. M., & McKenna, P. (1999). Abuse/misuse of non-prescription drugs. Pharmacy World Science, 21, 251-255.
18. Inciardi, J. A., Surratt, H. L., Kurtz, S. P., & Cicero, T. J. (2007). Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Medicine, 8, 171-183.
19. Joranson, D. E., & Gilson, A. M. (1998). Regulatory barriers to pain management. Seminars in Oncology Nursing, 14, 158-163.
20. MacDonald, D., Neville, D., & Priddle, M. (2005). Community pharmacists' expectations of a pharmacy network: a baseline evaluation. Canadian Pharmacy Journal, 138, 50-58.
21. Manchikanti, L. (2006). Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician, 9, 287-321.
22. McCabe, S. E., Cranford, J. A., Boyd, C. J., & Teter, C. J. (2007). Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addiction Behaviour, 32, 562-575.
23. Monga, N., Rehm, J., Fischer, B., Brissette, S., Bruneau, J., & El Guebaly, N., et al. (2007). Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug Alcohol Dependency, 88, 1-8.
24. Neutel, C. I. (2005). The epidemiology of long-term benzodiazepine use. International Review of Psychiatry, 17, 189-197.
25. Newfoundland, Labrador Pharmacy Board. (2004). Guidelines for the supply of exempted codeine products.
26. Office of National Drug Control Policy. (2006). Heroin Facts & Figures. Office of national Drug Control Policy [On-line]. Available at: http://www.whitehousedrugpolicy.gov/drugfact/heroin/index.html.
27. Oxycontin Task Force. (2004). Oxycontin Task Force, final report. Accessed from http://www.health.gov.nl.ca/ health/publications/oxyfinal/ OxyContinFinalReport.pdf.
28. Patton, D., & Adlaf, E. M. (2005). Canadian Addiction Survey (CAS): A national survey of Canadians' use of alcohol and other drugs: Prevalence of harms: Detailed report. Ottawa: Canadian Center on Substance Abuse.
29. PMP Bulletin, NSPMP. (2006). Prescription monitoring in Nova Scotia. PMP Bulletin, NSPMP. (2007). Patient Information.
30. Popova, S., Rehm, J., & Fischer, B. (2006). An overview of illegal opioid use and health services utilization in Canada. Public Health, 120, 320-328.
31. Poulin, C. (2001). Medical and nonmedical stimulant use among adolescents: From sanctioned to unsanctioned use. Canadian Medical Association Journal, 165, 1039-1044.
32. Prince Edward Island Pharmacy Board. (2004). Guidelines for the supply of exempted codeine products.
33. Rehm, J., Baliunas, D., Brochu, S., Fischer, B., Gnam, W., & Patra, J., et al. (2006). The costs of substance abuse in Canada.
34. Richard, J., & Reidenberg, M. M. (2005). The risk of disciplinary action by state medical boards against physicians prescribing opioids. Journal of Pain Symptom Management, 29, 206-212.
35. Ritter, A., & Di Natale, R. (2005). The relationship between take-away methadone policies and methadone diversion. Drug and Alcohol Review, 24, 347-352.
36. Sibbald, B. (2005). Tighten Ontario's methadone program states inquest. Canadian Medical Association Journal, 172, 319-320.
37. Simoni-Wastila, L., & Tompkins, C. (2001). Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Substance Use and Misuse, 36, 1275-1296.
38. Sproule, B. A., Busto, U. E., Somer, G., Romach, M. K., & Sellers, E. M. (1999). Characteristics of dependent and nondependent regular users of codeine. Journal of Clinical Psychopharmacology, 19, 367-372.
39. Standard of Pharmacy Practice adopted by the Newfoundland and Labrador Pharmacy Board. ( 2004). Guidelines for the supply of exempted codeine products. Avaliable on line:
40. Standard of Pharmacy Practice adopted by the PEI Pharmacy Board. (2004). Guidelines for the supply of exempted codeine products. Avaliable on line:
41. Strang, D., & Rashiq, S. (2005). The illicit sale of prescribed opioid medications in Edmonton. Pain Research Management, 10, 188-189.
42. Tjepkema, M. (2004). Alcohol and illicit drug dependence. Health Reports, 15(Suppl), 9-19.
43. Wall, R., Rehm, J., Fischer, B., Brands, B., Gliksman, L., & Stewart, J., et al. (2000). Social costs of untreated opioid dependence. Journal of Urban Health, 77, 688-722.
44. Wardman, D., Khan, N., & El Guebaly, N. (2002). Prescription medication use among an aboriginal population accessing addiction treatment. Canadian Journal of Psychiatry, 47, 355-360.
45. Weekes, J., Rehm, J., & Mugford, R. (2007). Prescription drug abuse FAQs. Canadian Centre on Substance Abuse. Ottawa, Ontario, Canada.
46. Zacny, J., Bigelow, G., Compton, P., Foley, K., Iguchi, M., & Sannerud, C. (2003). College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug and Alcohol Dependence, 69, 215-232